Literature DB >> 34970035

Utilization of a SARS-CoV-2-positive donor for liver transplantation.

Anji E Wall1, Gregory J McKenna1, Nicholas Onaca1, Richard Ruiz1, Johanna Bayer1, Hoylan Fernandez1, Eric Martinez1, Amar Gupta1, Medhat Askar1,2, Cedric W Spak1,3, Giuliano Testa1.   

Abstract

Liver transplantation rates have been negatively affected by the pandemic caused by coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Current practice in the liver transplant community is to avoid utilizing SARS-CoV-2-positive donors for liver transplantation unless there is a compelling reason such as recipient illness severity. In this case, we report the use of a donor who had a positive exposure to and symptom history for COVID-19 and tested positive for SARS-CoV-2 on admission for a liver transplant recipient with primary sclerosing cholangitis and a Model of End-Stage Liver Disease score of 23 with no known COVID-19 exposures. We focus on the decision to accept this particular organ, as well as the discussion with the recipient about the unknowns of disease transmission and risk associated with this donor. The current case argues that transplant programs should begin to consider low-risk donors with positive SARS-CoV-2 testing for recipients who have the potential to benefit from liver transplantation, which may not only be those with the most severe illness.
Copyright © 2021 Baylor University Medical Center.

Entities:  

Keywords:  COVID-19; liver allocation; liver transplantation

Year:  2021        PMID: 34970035      PMCID: PMC8682856          DOI: 10.1080/08998280.2021.1985888

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  6 in total

1.  Emerging evidence to support not always "just saying no" to SARS-CoV-2 positive donors.

Authors:  Olivia S Kates; Cynthia E Fisher; Robert M Rakita; Jorge D Reyes; Ajit P Limaye
Journal:  Am J Transplant       Date:  2020-06-18       Impact factor: 8.086

Review 2.  Impact of the COVID-19 pandemic on liver donation and transplantation: A review of the literature.

Authors:  Riccardo De Carlis; Ivan Vella; Niccolò Incarbone; Leonardo Centonze; Vincenzo Buscemi; Andrea Lauterio; Luciano De Carlis
Journal:  World J Gastroenterol       Date:  2021-03-14       Impact factor: 5.742

3.  SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission.

Authors:  Victor M Corman; Holger F Rabenau; Ortwin Adams; Doris Oberle; Markus B Funk; Brigitte Keller-Stanislawski; Jörg Timm; Christian Drosten; Sandra Ciesek
Journal:  Transfusion       Date:  2020-05-27       Impact factor: 3.337

Review 4.  Utilization of deceased donors during a pandemic: argument against using SARS-CoV-2-positive donors.

Authors:  Malay B Shah; Raymond J Lynch; Hanine El-Haddad; Brianna Doby; Diane Brockmeier; David S Goldberg
Journal:  Am J Transplant       Date:  2020-06-09       Impact factor: 9.369

Review 5.  The Impact of COVID-19 on Organ Donation, Procurement, and Liver Transplantation in the United States.

Authors:  Jonathan Merola; Michael L Schilsky; David C Mulligan
Journal:  Hepatol Commun       Date:  2020-10-18

6.  Liver transplantation performed in a SARS-CoV-2 positive hospitalized recipient using a SARS-CoV-2 infected donor.

Authors:  Tommaso Maria Manzia; Carlo Gazia; Ilaria Lenci; Roberta Angelico; Luca Toti; Andrea Monaco; Alessandro Anselmo; Leonardo Baiocchi; Paolo Grossi; Giuseppe Tisone
Journal:  Am J Transplant       Date:  2021-03-17       Impact factor: 9.369

  6 in total
  2 in total

1.  Low risk high reward: What should we worry about with coronavirus disease 2019 positive donors?

Authors:  Emily M Eichenberger; Daniel R Kaul; Cameron R Wolfe
Journal:  Transpl Infect Dis       Date:  2022-07-12

2.  Organ transplantation using COVID-19-positive deceased donors.

Authors:  Matthew J Bock; Gabrielle R Vaughn; Peter Chau; Jennifer A Berumen; John J Nigro; Elizabeth G Ingulli
Journal:  Am J Transplant       Date:  2022-07-25       Impact factor: 9.369

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.